In addition, BioNTech will gain a state-of-the-art biologics manufacturing facility to contribute to its future global manufacturing and supply, and more than 300 Biotheus employees in R&D, ...
Acquisition to support the global execution of BioNTech’s oncology strategy and provide full global rights to BNT327/PM8002, an investigational ...
Seeking Alpha on MSN9h
BioNTech to buy bispecific antibody developer Biotheus for up to $950MBioNTech (BNTX) said the merger will strengthen its capabilities in developing, manufacturing and commercializing bispecific antibodies and treatment combinations. It will also expand the company’s ...
The tie-up will also expand BioNTech's footprint in China, giving it a local research and development hub for clinical trials, as well as a new biologics manufacturing facility and more than 300 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback